Home > Back to Publisher > Report Information

Diabetes Pipeline: Intense Activity to Meet Unmet Need Report

CHI Insight Pharma Reports
September 1, 2010
140 Pages - SKU: CHI2816423

Abstract Table of Contents Related Reports

Diabetes has serious consequences if it is not well treated. In 2010, the global prevalence of diabetes was estimated to have reached 285 million and it is predicted to reach 438 million in 2030. Available agents provide imperfect control of the disease, and the medical need for better therapies is widely recognized. This report discusses:

Pros and cons of marketed therapies and snapshots of the global diabetes market
Development pipelines and approaches that are being taken
Anticipated FDA filing dates for significant new products
Profiles of selected companies that are active in the field, including major and emerging players as well as specialist companies
Global market forecast to 2014, accounting for impacts of generics and new therapies
Expert interviews

Additional Information

About the Author:

Peter Norman, MBA, PhD, is a pharmaceutical consultant and analyst based in Burnham Beeches, near Windsor, England. He has written and presented widely on various aspects of respiratory disease, drug development, and the analysis of diverse therapeutic markets. Dr. Norman has over 20 years of experience of the pharmaceutical industry in both R&D and competitive intelligence. His publications include many reviews, 16 original scientific papers, and 11 patents, together with a number of management reports. The latter have been published by a number of companies, including Business Insights, FT Pharmaceuticals, Urch Publications, SMi, Decision Resources, Informa, and Insight Pharma (CHI). Dr. Norman holds science degree from Cambridge University and Brunel University and an MBA degree from the Open University.

CHAPTER 1
INTRODUCTION: 1.1. What is Diabetes?; 1.2. Diabetic Complications; 1.3. The Need for Improved Disease Control
CHAPTER 2
DIABETES: 2.1. Pathophysiology; 2.2. Diagnosis; 2.3. Incidence and Prevalence; 2.4. Current Treatment Options
CHAPTER 3: CURRENTLY MARKETED THERAPIES; 3.1. Introduction; 3.2. Insulin; 3.3. Metformin; 3.4. KATP Blockers; 3.5. PPAR Agonists; 3.6. Alpha−Glucosidase Inhibitors; 3.7. Incretin Modulators; 3.8. Combination Products; 3.9. Market Breakdown
CHAPTER 4: DEVELOPMENT PIPELINES; 4.1. Introduction; 4.2. Established Approaches
CHAPTER 5: COMPANY PROFILES; 5.1. Introduction; 5.2. Major Players; 5.3. Emerging Players; 5.4. Specialist Companies
CHAPTER 6: MARKET OUTLOOK; 6.1. Introduction; 6.2. The Impact of Generics; 6.3. The Impact of New Therapies; 6.4. Market Development
CHAPTER 7: EXPERT INTERVIEWS
REFERENCES
GLOSSARY
COMPANY INDEX
TABLES: Table 1.1. Advantages and Disadvantages of Classes of Drugs Used To Treat Type II Diabetes; Table 3.1. Global Sales in 2009 of Modified Insulins; Table 3.2. Significant KATP Channel Modulators and 2009 Sales; Table 3.3. Global Sales in 2009 of Approved DPP IV Inhibitors; Table 3.4. Global Sales in 2009 of Leading Branded Combination Products; Table 4.1. Insulin Formulations in Development; Table 4.2. PPAR Agonists in Development; Table 4.3. Other Development Products Acting on Established Targets; Table 4.4. Exenatide Formulations in Development; Table 4.5. Novel GLP-1 Analogs in Development; Table 4.6. DPP IV Inhibitors in Development; Table 4.7. SGLT2 Inhibitors in Development; Table 4.8. Glucokinase Activators in Development; Table 4.9. 11â-HSD1 Inhibitors in Development; Table 4.10. PTP1B Inhibitors in Development; Table 4.11. GPR119 Agonists in Development; Table 4.12. DGAT-1 Inhibitors in Development; Table 4.13. SCD1 Inhibitors in Development; Table 4.14. TGR5 Agonists in Development; Table 4.15. FBP Inhibitors in Development; Table 4.16. Glycogen Phosphorylase Inhibitors in Development; Table 4.17. AMPKa Modulators in Development; Table 4.18. SIRT1 Activators in Development; Table 4.19. Other Orally Active Antidiabetic Drugs in Development; Table 4.20. Other Biological Agents in Development for the Treatment of Diabetes; Table 5.1. Eli Lilly’s Development Pipeline of Diabetes Products; Table 5.2. GlaxoSmithKline’s Development Pipeline of Diabetes Products; Table 5.3. Merck’s Development Pipeline of Diabetes Products; Table 5.4. Novo Nordisk’s Development Pipeline of Diabetes Products; Table 5.5. sanofi-aventis’ Development Pipeline of Diabetes Products; Table 5.6. Takeda’s Development Pipeline of Diabetes Products; Table 5.7. Amgen’s Development Pipeline of Diabetes Products; Table 5.8. Astellas’ Development Pipeline of Diabetes Products; Table 5.9. AstraZeneca’s Development Pipeline of Diabetes Products; Table 5.10. Boehringer Ingelheim’s Development Pipeline of Diabetes Products; Table 5.11. Bristol-Myers Squibb’s Development Pipeline of Diabetes Products; Table 5.12. Novartis’ Development Pipeline of Diabetes Products; Table 5.13. Pfizer’s Development Pipeline of Diabetes Products; Table 5.14. Roche’s Development Pipeline of Diabetes Products; Table 5.15. Amylin’s Development Pipeline of Diabetes Products; Table 5.16. Arisaph’s Development Pipeline of Diabetes Products; Table 5.17. Biodel’s Development Pipeline of Diabetes Products; Table 5.18. DARA BioSciences’ Development Pipeline of Diabetes Products; Table 5.19. Diabetology’s Development Pipeline of Diabetes Products; Table 5.20. DiaMedica’s Development Pipeline of Diabetes Products; Table 5.21. Diasome’s Development Pipeline of Diabetes Products; Table 5.22. Ipsen’s Development Pipeline of Diabetes Products; Table 5.23. Metabolex’ Development Pipeline of Diabetes Products; Table 5.24. Piramal’s Development Pipeline of Diabetes Products; Table 5.25. Poxel’s Development Pipeline of Diabetes Products; Table 5.26. Theracos’ Development Pipeline of Diabetes Products; Table 5.27. TransTech Pharma’s Development Pipeline of Diabetes Products
FIGURES: Figure 1.1. Schematic of Treatment Regimen for Diagnosed Type II Diabetics; Figure 3.1. Global Diabetes Market 2009, Market Share by Therapeutic Class; Figure 3.2. Global Diabetes Market 2009, Market Share by Company; Figure 6.1. Anticipated FDA Filing Dates for Significant New Products; Figure 6.2. Forecast Share by Therapeutic Class of Global Diabetes Market in 2014

Diabetes Pipeline: Intense Activity to Meet Unmet Need Report

Share this report

Other tasks

Research Assistance

Related Markets

Diabetes Reports

Free Alert Me service